Stocks › CYTK
CYTOKINETICS INC
CYTK·Nasdaq·
United States·USD
$50.78
-0.68 (-1.32%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
CYTK
CYTOKINETICS INC · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
CYTKS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of CYTK by members of U.S. Congress · 5 on record · 2 in the last 12 months
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Gilbert Ray Cisneros, Jr.House · D · CA |
CYTKCYTOKINETICS INC · Stock |
Purchase $1,001 - $15,000 |
Oct 12, 2026 | Sep 29, 2026 | Filing ↗ |
Gilbert Ray Cisneros, Jr.House · D · CA |
CYTKCYTOKINETICS INC · Stock |
Purchase $1,001 - $15,000 |
Jul 2, 2026 | Jun 30, 2026 | Filing ↗ |
Gilbert Ray Cisneros, Jr.House · D · CA |
CYTKCYTOKINETICS INC · Stock |
Purchase $1,001 - $15,000 |
Nov 18, 2025 | Oct 9, 2025 | Filing ↗ |
Lisa C. McClainHouse · R · MI |
CYTKCYTOKINETICS INC · Stock |
Sale $1,001 - $15,000 |
Aug 13, 2025 | Jun 17, 2025 | Filing ↗ |
Lisa C. McClainHouse · R · MI |
CYTKCYTOKINETICS INC · Stock |
Purchase $1,001 - $15,000 |
Aug 13, 2025 | Jun 11, 2025 | Filing ↗ |
Whale Activity
Position changes in CYTK reported for 2026-09-30 by 535 institutional filers
- Increased204
- New59
- Held64
- Decreased125
- Closed62
- No prior filing21
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 21.0M | $1.39B | increased |
| T. Rowe Price Investment Management, Inc. | 18.9M | $1.25B | increased |
| WELLINGTON MANAGEMENT GROUP LLP | 10.6M | $698.0M | increased |
| STATE STREET CORP | 7.1M | $470.8M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6.8M | $448.2M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.3M | $413.0M | increased |
| Avoro Capital Advisors LLC | 4.9M | $323.0M | decreased |
| BANK OF AMERICA CORP /DE/ | 4.7M | $312.1M | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 3.8M | $248.4M | increased |
| Polar Capital Holdings Plc | 9.6M | $227.7M | increased |
| Invesco Ltd. | 3.0M | $198.8M | increased |
| RTW INVESTMENTS, LP | 2.9M | $188.6M | held |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by CYTK insiders, by quarter · Form 4
Recent Insider Transactions
2,400 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Malik Fady IbrahamEVP Research & Development | Sale | −3,300 | $51.73 | $171K | Nov 17, 2026 | Form 4 ↗ |
| Malik Fady IbrahamEVP Research & Development | Sale | −200 | $52.59 | $11K | Nov 17, 2026 | Form 4 ↗ |
| Hessekiel JeffreyChief Legal & Admin Officer | Sale | −15.1K | $52.62 | $795K | Nov 17, 2026 | Form 4 ↗ |
| Blum Robert IPresident & CEO · Director | Sale | −5,077 | $53.22 | $270K | Nov 16, 2026 | Form 4 ↗ |
| Blum Robert IPresident & CEO · Director | Sale | −2,223 | $54.08 | $120K | Nov 16, 2026 | Form 4 ↗ |
| Blum Robert IPresident & CEO · Director | Sale | −200 | $55.21 | $11K | Nov 16, 2026 | Form 4 ↗ |
| PARSHALL B LYNNEDirector · Director | Sale | −2,555 | $55.26 | $141K | Nov 9, 2026 | Form 4 ↗ |
| PARSHALL B LYNNEDirector · Director | Sale | −2,445 | $54.17 | $132K | Nov 9, 2026 | Form 4 ↗ |
| Malik Fady IbrahamEVP Research & Development | Sale | −3,500 | $62.93 | $220K | Nov 3, 2026 | Form 4 ↗ |
| Blum Robert IPresident & CEO · Director | Sale | −7,500 | $62.81 | $471K | Nov 2, 2026 | Form 4 ↗ |
| Malik Fady IbrahamEVP Research & Development | Sale | −3,500 | $64.01 | $224K | Oct 20, 2026 | Form 4 ↗ |
| Blum Robert IPresident & CEO · Director | Sale | −7,500 | $62.88 | $472K | Oct 12, 2026 | Form 4 ↗ |
| Malik Fady IbrahamEVP Research & Development | Sale | −3,500 | $61.38 | $215K | Oct 6, 2026 | Form 4 ↗ |
| Blum Robert IPresident & CEO · Director | Sale | −7,500 | $65.46 | $491K | Sep 28, 2026 | Form 4 ↗ |
| Blum Robert IPresident & CEO · Director | Option exercise | +7,500 | $10.60 | $80K | Sep 28, 2026 | Form 4 ↗ |
| Malik Fady IbrahamEVP Research & Development | Sale | −3,500 | $68.29 | $239K | Sep 22, 2026 | Form 4 ↗ |
| Malik Fady IbrahamEVP Research & Development | Option exercise | +3,500 | $7.80 | $27K | Sep 22, 2026 | Form 4 ↗ |
| Landry Robert EDirector | Sale | −1,000 | $72.13 | $72K | Sep 15, 2026 | Form 4 ↗ |
| Blum Robert IPresident & CEO · Director | Sale | −97.9K | $69.33 | $6.8M | Sep 15, 2026 | Form 4 ↗ |
| Blum Robert IPresident & CEO · Director | Gift | +97.9K | $0.00 | $0 | Sep 14, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding CYTK · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| T. Rowe Price Capital Appreciation Fund T. ROWE PRICE CAPITAL APPRECIATION FUND, INC. | 6.3M | $535.5M | 0.76% | Jun 30, 2026 |
| iShares Core S&P Mid-Cap ETF iShares Trust | 4.6M | $395.8M | 0.32% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 4.3M | $367.5M | 0.02% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 3.4M | $289.2M | 0.35% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 3.1M | $265.3M | 0.14% | Jun 30, 2026 |
| VANGUARD HEALTH CARE FUND VANGUARD SPECIALIZED FUNDS | 3.3M | $257.7M | 0.68% | Jul 31, 2026 |
| SMALLCAP World Fund Inc | 3.0M | $255.3M | 0.27% | Jun 30, 2026 |
| Fidelity OTC Portfolio Fidelity Securities Fund | 2.3M | $175.1M | 0.41% | Jul 31, 2026 |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 2.0M | $168.0M | 0.73% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 1.8M | $152.8M | 0.32% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list CYTK's shares (CUSIP 23282W605), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Wellington Management Company LLPSCHEDULE 13G/A · passive (13G) · 10.7M shares7.3%
Nov 16, 2026 · ↗ - Wellington Investment Advisors Holdings LLPSCHEDULE 13G/A · passive (13G) · 10.7M shares7.7%
Nov 16, 2026 · ↗ - Wellington Group Holdings LLPSCHEDULE 13G/A · passive (13G) · 10.7M shares7.7%
Nov 16, 2026 · ↗ - Wellington Management Group LLPSCHEDULE 13G/A · passive (13G) · 10.7M shares7.7%
Nov 16, 2026 · ↗ - STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 7.1M shares5.1%
Nov 10, 2026 · ↗ - Wellington Investment Advisors Holdings LLPSCHEDULE 13G/A · passive (13G) · 7.1M shares5.1%
Aug 13, 2026 · ↗ - Wellington Group Holdings LLPSCHEDULE 13G/A · passive (13G) · 7.1M shares5.1%
Aug 13, 2026 · ↗ - Wellington Management Group LLPSCHEDULE 13G/A · passive (13G) · 7.1M shares5.1%
Aug 13, 2026 · ↗ - Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 5.2M shares3.9%
Jul 8, 2026 · ↗ - FMR LLCSCHEDULE 13G/A · passive (13G) · 5.2M shares3.9%
Jul 8, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming cytokinetics as client
- FARRAGUT PARTNERS LLPCYTOKINETICS INC. · 2026 Q3 · HCR$30K
Filing ↗ - FARRAGUT PARTNERS LLPCYTOKINETICS INC. · 2026 Q2 · HCR$30K
Filing ↗ - FARRAGUT PARTNERS LLPCYTOKINETICS INC. · 2026 Q1 · HCR$30K
Filing ↗ - FARRAGUT PARTNERS LLPCYTOKINETICS INC. · 2025 Q4 · HCR$30K
Filing ↗ - FARRAGUT PARTNERS LLPCYTOKINETICS INC. · 2025 Q3 · HCR$30K
Filing ↗
Government Contracts
Federal awards to CYTOKINETICS INC · USAspending
No federal contract awards found for CYTOKINETICS INC.
U.S. Patents
Recent USPTO applications naming CYTOKINETICS INC
No USPTO patent applications found for CYTOKINETICS INC.
Annual Financials
From CYTK's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $88.0M | $18.5M | $7.5M | $94.6M | $70.4M |
| Operating income | -$612.3M | -$536.2M | -$496.2M | -$324.2M | -$186.3M |
| Net income | -$785.0M | -$589.5M | -$526.2M | -$389.0M | -$215.3M |
| Diluted EPS | -$6.54 | -$5.26 | -$5.45 | -$4.33 | -$2.80 |
| Operating cash flow | -$510.0M | -$395.9M | -$414.3M | -$299.5M | -$142.5M |
| Cash and equivalents | $122.5M | $94.9M | $113.0M | $65.6M | $112.7M |
| Total assets | $1.42B | $1.40B | $824.3M | $1.01B | $841.3M |
| Total liabilities | $2.08B | $1.54B | $1.21B | $1.12B | $597.5M |
| Shareholders' equity | -$659.6M | -$135.4M | -$386.3M | -$107.9M | $243.9M |
As CYTOKINETICS INC tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 26, 2026 ↗
Stock Splits
Every split and reverse split in the price history
- 1-for-6Reverse splitJun 25, 2013
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 2.02, 9.01Results of operationsNov 4, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsAug 28, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsAug 13, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 6, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteMay 27, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsMay 8, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsMay 5, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 5, 2026
EDGAR ↗
About CYTOKINETICS INC
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersSOUTH SAN FRANCISCO, CA
SEC CIK0001061983 ↗


